Meronem (Meropenem)

Meropenem is a broad‑spectrum carbapenem used to treat severe infections caused by Gram‑negative and Gram‑positive bacteria.

• Complicated intra‑abdominal infections: achieves clinical cure and bacterial eradication in patients with polymicrobial peritonitis.
• Complicated urinary tract infections: provides effective bacterial clearance in cases resistant to other agents.
• Nosocomial pneumonia: improves outcomes in ventilator‑associated and hospital‑acquired pneumonia.
• Septicemia: rapidly reduces bacteremia and supports hemodynamic recovery.
• Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis.

• Meropenem exerts its antibacterial activity by binding to penicillin‑binding proteins (PBPs) on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic lysis and bacterial death. The molecule is stable against most β‑lactamases, allowing it to retain activity against multidrug‑resistant Gram‑negative and Gram‑positive organisms.

Adverse reactions to Meropenem vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Vomiting: occasional emesis following infusion.
• Diarrhea: loose stools, may be self‑limiting.
• Infusion site reactions: erythema or pain at the injection site.
• Elevated liver enzymes: transient increase in ALT/AST.
• Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects

• Seizures: risk increased in patients with renal impairment or CNS disorders.
• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Clostridioides difficile colitis: potential for severe intestinal infection.
• Thrombocytopenia: marked reduction in platelet count.
• Renal toxicity: acute kidney injury in susceptible individuals.
• Severe neutropenia: marked decrease in neutrophil count.

When using Meropenem, clinicians should consider several precautionary measures to ensure safe therapy.

• Renal impairment: adjust dose according to creatinine clearance.
• History of seizures: monitor for neurotoxicity and consider alternative agents.
• Pregnancy Category B: use only when the potential benefit justifies the potential risk to the fetus.
• Allergy to β‑lactams: assess cross‑reactivity before initiating therapy.
• Concurrent valproic acid therapy: avoid due to increased risk of seizures.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Valproic acid: concomitant use can lower valproate levels and increase seizure risk.
• Nephrotoxic agents (e.g., aminoglycosides): combined high doses may exacerbate renal injury.

Moderate Interactions (Monitor Closely)

• Loop diuretics: monitor renal function and electrolytes.
• Warfarin: observe INR values for potential anticoagulation changes.
• Oral contraceptives: efficacy may be reduced; advise alternative contraception.
• Other antibiotics: assess for antagonistic effects when used together.